Welcome to our dedicated page for Nkarta news (Ticker: NKTX), a resource for investors and traders seeking the latest updates and insights on Nkarta stock.
Nkarta, Inc. reports developments as a clinical-stage biotechnology company developing allogeneic, off-the-shelf engineered natural killer (NK) cell therapies for autoimmune diseases. Company updates center on NKX019, an investigational CAR-NK cell therapy for B cell-mediated autoimmune diseases, and on the Ntrust-1 and Ntrust-2 clinical studies.
Recurring news themes include FDA protocol discussions, outpatient dosing plans, dose-escalation updates, B-cell depletion data, preclinical and clinical presentations, quarterly financial results, cash runway commentary, workforce and operating updates, and participation in healthcare and investor conferences.
Nkarta, Inc. (Nasdaq: NKTX) reported its financial results for Q4 and the full year 2022, highlighting a net loss of $113.8 million or $2.61 per share. As of December 31, 2022, the company had cash and equivalents of $354.9 million, projected to fund operations into 2025. Nkarta is advancing its NKX101 and NKX019 therapies, with clinical updates expected in 2023. NKX101 showed a 60% complete response rate in r/r AML patients, while NKX019 demonstrated a 70% complete response in relapsed/refractory B-cell malignancies. Both therapies appear well-tolerated, with no significant toxicity reported.
Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company focused on engineered natural killer (NK) cell therapies for cancer, announced its participation in three notable investor conferences. The events include the SVB Securities Global Biopharma Conference on February 14, 2023, where a fireside chat is slated for 3:40 p.m. ET; the H.C. Wainwright Cell Therapy Virtual Conference on February 28, 2023, with timing to be determined; and the Cowen 43rd Annual Health Care Conference on March 8, 2023, featuring an industry panel discussion at 2:10 p.m. ET. Webcasts of the events will be accessible on Nkarta’s website, with replays available for 90 days.
Nkarta, Inc. (Nasdaq: NKTX) has announced the promotion of Dr. David R. Shook to Chief Medical Officer. Dr. Shook has significant expertise in NK cell therapy and has been with Nkarta since 2020, previously serving as Vice President of Clinical Development. His leadership is expected to enhance the company's clinical strategy and development of cell therapies. Nkarta focuses on engineered NK cell therapies to treat cancer, aiming for broad access and impactful patient treatment. Forward-looking statements caution on risks and uncertainties affecting Nkarta's clinical outcomes and financial position.
Nkarta, Inc. (NASDAQ: NKTX) reported promising results from its Phase 1 dose escalation study of NKX019, an engineered NK cell therapy for relapsed or refractory non-Hodgkin lymphoma (NHL). Notably, 7 out of 10 patients treated at higher doses achieved a complete response (70% CR rate). Five complete responses were achieved after a single treatment cycle, with durable responses lasting over six months in several cases. The therapy demonstrated a favorable safety profile, with no significant toxicities observed. Nkarta is expanding the study with combination therapies and plans to share further updates in 2023.
Nkarta, Inc. (Nasdaq: NKTX) announces a conference call on December 5, 2022, at 8:00 a.m. ET to discuss updated clinical data from its ongoing Phase 1 trial of NKX019, a CD19-directed CAR NK cell therapy. NKX019 is designed to treat relapsed/refractory B cell malignancies and is being assessed for safety and anti-tumor activity as both monotherapy and combination therapy. The call will provide vital insights into the therapy's progress, and accompanying slides will be accessible on Nkarta's website.
Nkarta, a clinical-stage biopharmaceutical company, reported significant clinical advancements in its NKX101 and NKX019 programs. As of Sept 30, 2022, cash reserves totaled $395.1 million. The company has opened dose expansion cohorts for NKX019 and anticipates clinical updates for both NKX019 and NKX101 in 2022 and 2023, respectively. During Q3 2022, R&D expenses were $23.4 million, contributing to a net loss of $28.3 million, or $0.58 per share. Despite losses, Nkarta expects sufficient cash to sustain operations into 2025.
Nkarta, Inc. (Nasdaq: NKTX) presented two preclinical data abstracts at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting. Notably, NKX019, a CAR NK cell, demonstrated improved anti-tumor activity when combined with CD20 antibodies like rituximab. Additionally, the company's proprietary manufacturing platform achieved over a billion-fold expansion of NK cells while preserving potency, enabling potential commercial-scale therapy production from a single donor. Nkarta aims to enhance cancer treatment accessibility through engineered NK cell therapies.
Nkarta (Nasdaq: NKTX), a biopharmaceutical company specializing in engineered natural killer (NK) cell therapies for cancer, has announced participation in three upcoming investor conferences. The Cowen IO Next Summit will take place on November 11, 2022, followed by the Stifel Healthcare Conference on November 15, 2022, and the Evercore ISI HealthCONx Conference on November 29, 2022. Each event will feature a fireside chat, and webcasts will be available on Nkarta's website, with replays accessible for 90 days.
Nkarta, Inc. reported positive preliminary data from its NKX101 and NKX019 Phase 1 studies in patients with relapsed/refractory AML and NHL, validating its CAR NK cell therapy platform. Financial results for Q2 2022 showed a net loss of $27.0 million or $0.61 per share. Nkarta held $415.0 million in cash and equivalents as of June 30, 2022, with R&D expenses at $21.0 million. The company anticipates further clinical data by year-end 2022, including safety and activity results at increased dosages. Nkarta aims to leverage this data for advancing its promising cancer therapies.
Nkarta, Inc. (Nasdaq: NKTX) recently announced the promotions of Ralph Brandenberger, PhD, to Chief Technical Officer and Yvonne Li, MBA, to Chief Administrative Officer. These changes are part of Nkarta's leadership evolution as it prepares for the commercialization of its off-the-shelf NK cell therapies. Dr. Brandenberger brings over 20 years of experience in biopharmaceutical manufacturing, while Ms. Li has nearly 25 years in corporate finance. Their leadership is expected to be vital as Nkarta advances in developing engineered NK cell therapies for cancer treatment.